Risk in CNS drug discovery: focus on treatment of Alzheimer's disease

Area of Science:

• Pharmacology and Drug Development
• Neuroscience
• Biotechnology

Background:

• Drug discovery and development face significant inherent risks despite advances in understanding disease mechanisms and identifying therapeutic targets.
• Stakeholder perspectives on risk vary, necessitating a comprehensive approach to risk assessment in drug research.
• Translating preclinical findings to human success is particularly challenging in neurodegenerative diseases, such as Alzheimer's disease, due to poor model predictivity, lengthy clinical trials, and evolving efficacy markers.

Purpose of the Study:

• To highlight the inherent risks in drug discovery and development.
• To emphasize the importance of understanding diverse stakeholder risk perspectives.
• To outline strategies for mitigating risks in drug development, particularly for neurodegenerative diseases.

Main Methods:

• Review of risk factors and management strategies in drug discovery.
• Analysis of challenges specific to neurodegenerative disease drug development.
• Examination of current therapeutic approaches in clinical development for Alzheimer's disease.

Main Results:

• Drug development is a high-risk endeavor influenced by multiple factors.
• Effective risk management strategies include meticulous candidate selection, expert team execution, and disciplined decision-making.
• Despite challenges, novel therapies with potentially synergistic mechanisms are advancing in clinical development for Alzheimer's disease.

Conclusions:

• Mitigating risks in drug discovery requires a multi-faceted approach encompassing scientific rigor, strategic planning, and stakeholder alignment.
• Addressing the unique challenges of neurodegenerative disease drug development is crucial for advancing patient care.
• The development of innovative therapies offers hope for influencing the course of diseases like Alzheimer's.